D. E. Shaw & Co., Inc. Immatics N.V. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$81.7 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$79.1 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$66.1 Million2.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.38MShares$60.3 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$52.6 Million0.79% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $623M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...